{
    "nctId": "NCT00513292",
    "briefTitle": "Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery",
    "officialTitle": "A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients With HER-2 Positive Operable Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "HER2/Neu Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 280,
    "primaryOutcomeMeasure": "pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of invasive adenocarcinoma by core needle biopsy\n\n  * Fine needle aspiration allowed provided primary tumor size \\< 2 cm and lymph node metastases are present\n  * Excisional biopsy of the primary tumor allowed provided biopsy-positive lymph nodes are present\n* Primary tumor \u2265 2 cm and/or \u2265 1 biopsy-positive lymph node\n* HER2-positive disease\n\n  * Confirmation by fluorescent in situ hybridization (FISH) requires gene amplification\n  * Confirmation by immunohistochemistry (IHC) requires a strongly positive (3+) staining intensity score\n* Ductal carcinoma in situ (DCIS) or synchronous DCIS of the contralateral breast regardless of prior therapy allowed\n\n  * Synchronous invasive breast cancer not allowed\n* Ipsilateral DCIS treated by local excision with or without hormonal therapy allowed\n\n  * Those treated with radiation therapy are not allowed\n* No definitive clinical or radiologic evidence of metastatic disease\n* No history of invasive breast cancer\n* Hormone receptor status known\n* Menopausal status not specified\n* ECOG performance status of 0 -1\n* Absolute neutrophil count \u2265 1,200/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Total bilirubin normal unless the patient has a grade 1 bilirubin elevation (normal to 1.5 times upper limit of normal \\[ULN\\]) resulting from Gilbert disease or similar syndrome due to slow conjugation of bilirubin\n* Alkaline phosphatase \u2264 2.5 times ULN\n* AST \u2264 1.5 times ULN\n* Creatinine normal\n* Left ventricular ejection fraction (LVEF) \u2265 55 by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within the past 3 months\n* Patients with either skeletal pain or alkaline phosphatase that is \\> ULN but \u2264 2.5 times ULN allowed if bone scans fail to demonstrate metastatic disease\n\n  * Suspicious findings on bone scan must be confirmed as benign by x-ray, MRI, or biopsy\n* Prior non-breast malignancies allowed if disease-free for 5 years since completion of initial treatment regimen and deemed by their physician to be at low risk for recurrence\n\n  * Patients who had the following cancers are eligible if diagnosed and treated within the past 5 years:\n\n    * Carcinoma in situ of the cervix\n    * Colon carcinoma in situ\n    * Melanoma in situ\n    * Basal cell and squamous cell carcinoma of the skin\n* No cardiac disease that would preclude the use of epirubicin hydrochloride or trastuzumab (Herceptin\u00ae) including any of the following:\n\n  * Active cardiac disease\n  * Angina pectoris that requires the use of antianginal medication\n  * Cardiac arrhythmia requiring medication\n  * Severe conduction abnormality\n  * Clinically significant valvular disease\n  * Cardiomegaly on chest x-ray\n  * Ventricular hypertrophy on EKG\n  * Patient's with poorly controlled hypertension ( i.e., diastolic greater than 100 mm/Hg)\n\n    * Patients with hypertension that is well controlled on medication are eligible\n  * History of cardiac disease\n  * Myocardial infarction documented as a clinical diagnosis or by EKG or any other tests\n  * Documented congestive heart failure\n  * Documented cardiomyopathy\n* No sensory or motor neuropathy \u2265 grade 2, as defined by the NCI's CTCAE v3.0\n* Women of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy\n* Women of child bearing potential must have a negative urine or serum pregnancy test within 2 weeks of registration\n* Not pregnant or nursing\n* No psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements\n* No non-malignant systemic disease (e.g., cardiovascular, renal, hepatic) that would preclude treatment with either of the treatment regimens\n* No prior surgical axillary staging procedure\n\n  * Prior non-excisional biopsy of an axillary node allowed\n* No prior treatment for this breast cancer\n\n  * Hormonal therapy allowed if had been given for up to a total of 28 days anytime after diagnosis and before study entry\n  * Hormonal therapy must stop at or before study entry and be re-started, if indicated, following surgery\n* No prior therapy with anthracyclines or taxanes for any malignancy\n* No other investigational agents within the past 30 days\n* No concurrent sex hormonal therapy (e.g., birth control pills, ovarian hormonal replacement therapy)\n* No concurrent therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulator (SERM), either for osteoporosis or breast cancer prevention",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}